Dr. Lal Pathlabs Limited — Regulatory Filings 2021

Feb 18, 2021

==> picture [24 x 38] intentionally omitted <==

==> picture [251 x 29] intentionally omitted <==

February 18, 2021

National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Sandra Kurla Complex Sandra (E), Mumbai - 400 051

Kind Attn: Mr. Sareesh Koroth, Chief Manager, Surveillance

Subject: Increase in Volume

Dear Sir,

This is with reference to your letter NSE/CM/Surveillance/10410 dated February 17, 2021 received through email with respect to the captioned subject.

In this respect, the Company wishes to inform you that currently there is no such announcement or price sensitive information, which· is pending to be intimated by the Company to the Stock Exchanges concerning its performance/operations required to be disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The spurt in volume of the scrip of the Company in recent past is absolutely market driven and the Company has no comments to offer on this.

We wish to reiterate and clarify that all the information furnished by the Company is in public domain and the Company will comply with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and keep the Stock Exchanges duly informed of all the price sensitive information(s).

Thanking You,

Yours Faithfully,

==> picture [73 x 75] intentionally omitted <==

ecretary and Legal Head

Regd. Office: Dr. Lal Pathlab5 Ltd., Blod< E, Sector-I B. Roh1rn, New Delhi - I I 0065, +91-11-30256600. Fax: +91-11-2788-2134 Corporate Office: Dr. Lal PathLabs Ltd., 12th Floor, Tower B, SAS Tower, Medici!}', Sector-38, Gurugram - 122 00 I, Haryana +91-124-3016-500, Fax: +91-124-4234-468 �aif.:__l;1foorhl.;1h,;lrublnAthl�h .. ,:om \Y/,: h• WUAA1 .. blo.2f-hbbc. r�n-,, ro�., ,., .... • L.24.QQO I 1 oai=.01-.eoL.c;�oo